Table 1.
Changes in clinical measures of disease activity over 12 weeks on anti-TNF treatment in 25 patients with rheumatoid arthritis
| Parameter | Baseline | Week 1 | Week 4 | Week 12 | |||
|---|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | P value | Mean ± SD | P value | Mean ± SD | P value | |
| DAS28-ESR | 5.72 ± 0.84 | 4.47 ± 1.14 | **** | 4.26 ± 1.13 | **** | 2.87 ± 1.11 | **** |
| DAS28-CRP | 5.28 ± 0.98 | 3.98 ± 1.09 | **** | 3.85 ± 1.13 | **** | 2.36 ± 1.04 | **** |
| SJC28 | 7.68 ± 5.36 | 4.42 ± 3.89 | ** | 4.54 ± 4.28 | ** | 3.00 ± 3.83 | *** |
| TJC28 | 14.88 ± 8.51 | 8.95 ± 6.66 | *** | 8.76 ± 6.69 | ** | 4.68 ± 4.93 | *** |
| CRP | 15.74 ± 18.26 | 5.29 ± 6.39 | *** | 10.75 ± 24.15 | *** | 8.73 ± 16.48 | *** |
| ESR | 27.21 ± 22.67 | 20.50 ± 19.36 | ** | 19.96 ± 14.88 | ** | 20.45 ± 16.73 | ns |
Data are presented as mean ± SD. DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SJC28 swollen joint count out of 28 joints, TJC28 tender joint count out of 28 joints
Each time point on treatment was compared to baseline using Wilcoxon matched pairs test; **P < 0.001, ***P < 0.0005, ****P < 0.0001